Bremelanotide
Also known as: Vyleesi, PT-141, BMT
Bremelanotide is an FDA-approved melanocortin receptor agonist used to treat hypoactive sexual desire disorder in premenopausal women. This synthetic peptide works by activating melanocortin receptors in the central nervous system to enhance sexual arousal and desire.
Bremelanotide is a 1025.16 g/mol research peptide. Bremelanotide is an FDA-approved melanocortin receptor agonist used to treat hypoactive sexual desire disorder in premenopausal women. This synthetic peptide works by activating melanocortin receptors in the central nervous system to enhance sexual arousal and desire.
Also called: Vyleesi, PT-141, BMT
1025.16 g/mol
Molecular Weight
Daltons
3
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
1.75-1.75
Typical Dose
mg
Overview
Bremelanotide represents a novel approach to treating sexual dysfunction by targeting the brain's melanocortin system rather than vascular mechanisms like traditional treatments. The peptide binds to melanocortin-3 and melanocortin-4 receptors in the hypothalamus and other brain regions involved in sexual response. Unlike phosphodiesterase inhibitors that work peripherally, bremelanotide acts centrally to increase sexual motivation and arousal. Originally developed from melanotan-II, bremelanotide was specifically modified to reduce melanocortin-1 receptor activity, eliminating the skin-darkening effects while preserving its pro-sexual properties. Clinical trials demonstrated significant improvements in sexual desire and distress reduction in women with hypoactive sexual desire disorder, leading to FDA approval in 2019.
Key Takeaways: Bremelanotide
- Strongest evidence supports Bremelanotide for enhanced female sexual desire and reduced sexual distress
- Research doses typically range from 1.75 to 1.75 mg via subcutaneous
- 3 benefits with strong evidence, 2 moderate, 1 preliminary
- Half-life: 2.7 hours
- 4 cited research studies in this guide
Mechanism of Action
Bremelanotide functions as a non-selective agonist of melanocortin-3 and melanocortin-4 receptors in the central nervous system. Upon binding, it activates cyclic adenosine monophosphate signaling pathways that modulate neural circuits involved in sexual desire and arousal. The peptide specifically targets the paraventricular nucleus of the hypothalamus, where melanocortin receptors regulate sexual behavior. This central mechanism distinguishes it from peripheral treatments, as bremelanotide directly influences the brain's sexual motivation centers rather than simply improving blood flow or hormone levels.
Research Benefits
Bremelanotide at a Glance
Bremelanotide functions as a non-selective agonist of melanocortin-3 and melanocortin-4 receptors in the central nervous system.
Enhanced Female Sexual Desire
Strong EvidenceClinical trials show bremelanotide significantly increases sexual desire in premenopausal women with hypoactive sexual desire disorder, with 25% more women achieving meaningful improvements compared to placebo.
Reduced Sexual Distress
Strong EvidenceStudies demonstrate substantial reductions in distress related to low sexual desire, with participants reporting improved quality of life and relationship satisfaction.
Non-Hormonal Mechanism
Strong EvidenceUnlike hormone replacement therapy, bremelanotide works through neurotransmitter pathways, offering an alternative for women who cannot use hormonal treatments.
Central Nervous System Sexual Response
Moderate EvidenceBrain imaging studies confirm bremelanotide activates regions associated with sexual arousal including the hypothalamus, anterior cingulate cortex, and insula.
Rapid Onset of Action
Moderate EvidenceEffects typically begin within 45 minutes of administration, allowing for on-demand use rather than daily dosing requirements.
Potential Male Sexual Function
PreliminaryEarly research suggests possible benefits for erectile dysfunction in men through central melanocortin pathway activation, though this remains investigational.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Female sexual desire research | 1.75–1.75 mg | subcutaneous |
| Male sexual function research | 1–2 mg | subcutaneous |
Frequency
As needed, maximum once per 24 hours
Timing
45 minutes before intended activity
Cycle Length
No more than 8 doses per month
Research Notes
- 1FDA-approved dose is 1.75mg subcutaneously for women
- 2Maximum of 8 injections per month to prevent tolerance
- 3Rotate injection sites to prevent lipodystrophy
- 4Allow at least 24 hours between doses
Reconstitution Guide
Standard Reconstitution
Vial Size
1.75 mg
Bacteriostatic Water
0.5 mL
Concentration
35 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Bremelanotide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0.5 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C. 30 days refrigerated after reconstitution.
Storage Temperature
2-8°C
Shelf Life
30 days refrigerated after reconstitution
Important Notes
- •Available as pre-filled autoinjector pens
- •Store unopened vials in refrigerator
- •Allow to reach room temperature before injection
- •Single-use devices should not be reused
Bremelanotide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Bremelanotide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Nausea (most common, affects 40% of users)
- !Flushing and hot flashes
- !Headache
- !Vomiting
- !Injection site reactions
- !Decreased appetite
- !Darkening of gums, face, and breasts
- !Dizziness
- !Fatigue
- !Spontaneous penile erections (in males)
Potential Interactions
- ⚡Naltrexone may reduce effectiveness by blocking opioid pathways
- ⚡Alcohol may increase nausea and flushing side effects
- ⚡Blood pressure medications may have additive hypotensive effects
- ⚡Antidepressants may alter sexual response independently
- ⚡No significant interactions with hormonal contraceptives reported
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Efficacy and Safety of Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder
Phase 3 randomized controlled trial demonstrated significant improvements in sexual desire and reduced distress in 1267 premenopausal women with HSDD.
Bremelanotide for Treatment of Hypoactive Sexual Desire Disorder
Pooled analysis of two phase 3 trials confirmed efficacy and safety profile leading to FDA approval for female sexual desire disorder.
Central Effects of the Melanocortin Agonist Bremelanotide on Sexual Behavior
Preclinical studies demonstrated melanocortin-4 receptor activation in hypothalamic regions critical for sexual motivation and arousal.
Brain Activation Patterns Associated with Bremelanotide Treatment
Functional MRI studies showed increased activation in brain regions associated with sexual arousal following bremelanotide administration.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Bremelanotide typically begins working within 45 minutes of subcutaneous injection, with peak effects occurring 1-3 hours after administration.
While bremelanotide is only FDA-approved for women, research studies have investigated its use in men for erectile dysfunction. However, it is not currently approved for male sexual dysfunction.
Bremelanotide works centrally in the brain to increase sexual desire, while Viagra works peripherally to improve blood flow. Bremelanotide targets the cause of low desire rather than just physical arousal.
Bremelanotide can cause mild darkening of the gums, face, and breasts in some users, but this effect is much less pronounced than with melanotan-II due to reduced melanocortin-1 receptor activity.
Bremelanotide should not be used more than once in 24 hours and no more than 8 times per month to prevent tolerance and minimize side effects.
Bremelanotide should not be used during pregnancy or breastfeeding. Women who become pregnant should discontinue use and consult their healthcare provider.
Nausea is the most common side effect, affecting about 40% of users. Taking an anti-nausea medication 30 minutes before injection may help. If nausea persists, consult your healthcare provider.
Bremelanotide can generally be used with antidepressants, but some SSRIs may independently affect sexual function. Discuss potential interactions with your healthcare provider.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.